Connexa Sports Techs 株価情報 (NASDAQ: YYAI)

最新ニュース Connexa Sports Techs (NASDAQ:YYAI) 株価情報

Connexa Sports Technologies Inc. - Common Stock

Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.

Connexa Sports Technologies Inc

Dominari Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>) shares are trading higher in Monday&#8217;s after-hours session after Donald Trump Jr. and Eric Trump reported significant stakes<a href="https://www.benzinga.com/quote/DOMH/insider-trades"> in the company</a>.
What Happened: According to two separate regulatory <a href="https://www.sec.gov/Archives/edgar/data/12239/000121390025016616/xslSCHEDULE_13G_X01/primary_doc.xml">filings</a> released Monday, Trump Jr. and Eric Trump both reported stakes of 6.71% in Dominari Holdings as of Feb. 18.
The news comes after Dominari Holdings shares surged earlier this month after the company announced Trump Jr. and Eric Trump joined the company's board. They also participated in a private placement announced the same day.
"We are thrilled to welcome Don Jr. and Eric as advisors to our team. They have each achieved significant success across a wide range of industries and bring invaluable leadership and strategic insight that we believe will be highly beneficial for our firm," CEO&nbsp;Kyle Wool said at the time.
"Their&nbsp;guidance&nbsp;is expected to be instrumental as we continue to seek attractive investment opportunities, particularly in the rapidly evolving AI and Data Center sector."
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43924482/exclusive-3-etfs-positioned-for-microsofts-quantum-breakthrough">EXCLUSIVE: 3 ETFs Positioned For Microsoft&#8217;s Quantum Breakthrough</a>
Dominari Holdings shares&nbsp;are up approximately 670% year-to-date. The stock has seen increased attention this year as retail traders have highlighted the company's investments on social platforms. 
According to a filing showing holdings as of Sept. 31, 2024, Dominari maintains investments in several popular companies including&nbsp;Anduril,&nbsp;xAI,&nbsp;Epic Games,&nbsp;Discord&nbsp;and more.
DOMH Price Action: <a href="http://benzinga.com/quote/domh" target="_blank" rel="noreferrer noopener">Dominari Holdings shares</a> were up 23.48% after hours, trading at $9.36 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

News

After-Hours Center

Movers

DOMH

Dominari Holdings Stock Surges After Hours: What's Going On?

A recent Reddit <a href="https://www.reddit.com/r/stocks/comments/1it2hds/does_anyone_else_feel_uneasy_about_investing/">post</a> on r/stocks has caught the attention of many investors. The post, which got thousands of upvotes and comments, talks about concerns over President Donald Trump's new executive orders. The main worry is that these orders give the White House more control over financial agencies like the Securities and Exchange Commission and the Federal Trade Commission.
<h2 class="wp-block-heading">A New Level of Government Control</h2>
Trump's <a href="https://www.whitehouse.gov/presidential-actions/2025/02/ensuring-accountability-for-all-agencies/">executive order</a> now forces these agencies to report to the White House, which means they are no longer fully independent. The SEC and FTC are responsible for making sure businesses follow the rules, but now, their decisions could be influenced by politics.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
For investors, this shift raises serious concerns about market fairness and corporate accountability. Regulatory agencies play a key role in investigating corporate misconduct and ensuring market stability. If these agencies lose their independence, it could result in weaker enforcement, corporate favoritism, and market volatility.
<h2 class="wp-block-heading">Play It Safe or Stay the Course?</h2>
The investor posed a simple question on Reddit: &#8220;Does anyone else feel uneasy about investing given all of the U.S. President&#8217;s Executive Orders?&#8221; They continued, &#8220;The most recent EOs indicate intensified interference in the activities of the SEC and the FTC. This would most likely severely impact their operations. The other EO undermining the judiciary undermines the Rule of Law, which is of course also bad for business. I'm feeling really worried and am considering pulling out some of my investments and holding.&#8221;
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Reddit users and investors have different opinions about what to do next. Some say it's smart to hold more cash in case the market drops. Others think it's best to keep investing slowly over time while having extra cash ready if stocks suddenly get cheaper.
One user suggested keeping at least 20% of their money in cash to be safe. Another pointed out that holding too much cash might not be a good idea because inflation could lower its value over time.
<h2 class="wp-block-heading">Global Diversification and Safe Havens</h2>
Many investors are looking beyond U.S. markets, considering European defense stocks, cybersecurity firms, and international mutual funds. Some are even exploring multi-currency accounts as concerns grow over the long-term stability of the U.S. dollar.
The discussion also touched on the impact of new tariffs on chips and cars, which some believe could contribute to inflation and supply chain disruptions. If the Federal Reserve maintains high interest rates in response, it could further shake investor confidence.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">A Broader Power Grab?</h2>
This isn't the only executive order raising alarms. Trump has also fired 17 independent watchdogs, <a href="https://www.benzinga.com/25/01/43181433/trumps-birthright-citizenship-order-halted-by-judge-blatantly-unconstitutional">attempted to eliminate birthright citizenship</a>, and issued over <a href="https://www.benzinga.com/news/25/01/43088148/trump-pardons-1500-jan-6-defendants-including-key-proud-boys-figures-after-bidens-final-hour-clemency">1,500 pardons</a> related to the Jan. 6 Capitol riots. Some legal experts believe these moves are designed to test the limits of presidential power and could even be aimed at getting Supreme Court approval for expanding executive authority.
Trump's administration has also created the Department of Government Efficiency, which has been making deep cuts across federal agencies, including the United States Agency for International Development.
<h2 class="wp-block-heading">What's Next for Investors?</h2>
Stay invested and ride the wave, or move to safer assets as uncertainty looms? One thing is clear—no one really knows what's coming next. While some believe the stock market remains resilient, others argue that weakening regulatory institutions could make long-term investing riskier. If companies can operate with less oversight, short-term gains could be followed by long-term instability. Meanwhile, Congress has been largely silent, with Republicans offering little pushback to Trump's aggressive executive actions.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></li>
</ul>

'Bad For Business'—Investor Questions The Impact Of President's Executive Orders On The Market Due To 'Intensified Interference'

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 15 years by 8.57% on an annualized basis producing an average annual return of 20.4%. Currently, Visa has a market capitalization of $674.88 billion. 
Buying $1000 In V: If an investor had bought $1000 of V stock 15 years ago, it would be worth $16,118.87 today based on a price of $349.86 for V at the time of writing.
<h3>Visa's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740436217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Visa Stock In The Last 15 Years

On February 19, 2025, the Company approved and began executing a strategic restructuring program designed to reposition its organization and improve its cost structure.&nbsp;
As part of the 2025 Restructuring Program the Company plans on consolidating certain operations that are currently based in La Chaux-de-Fonds, Switzerland, and in Kolbermoor, Germany, respectively, into other lower cost locations owned by the Company.
As a result of the activities described above, the Company expects to recognize total pretax charges, consisting primarily of severance and other termination benefits, in the range of $6.1&nbsp;million to $7.2&nbsp;million.

COHU

Cohu Plans 7% Headcount Reduction, With Half From US And Europe And Half From Asia - Filing

Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/02/g43925466/diamondback-energy-inc-announces-fourth-quarter-and-full-year-2024-financial-and-operating-results"> from the quarter. </a>
The Details: Diamondback Energy reported quarterly revenue of $3.71 billion, which beat the analyst consensus estimate of $3.53 billion and is an increase over revenue of $2.23 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43920295/palantir-extends-losses-microsoft-slides-whats-driving-markets-monday">Palantir Extends Losses, Microsoft Slides: What&#8217;s Driving Markets Monday?&nbsp;</a>
Diamondback Energy&#8217;s fourth-quarter figures included: 
<ul>
<li>Average production of 475.9 MBO/d (883.4 MBOE/d).</li>
<li>Net cash provided by operating activities of $2.3 billion; Operating Cash Flow Before Working Capital Changes of $2.3 billion.</li>
<li>Cash capital expenditures of $933 million.</li>
<li>Free Cash Flow of $1.3 billion; Adjusted Free Cash Flow of $1.4 billion.</li>
</ul>
Outlook: The company sees full-year 2025 oil production of between 485 and 498 MBO/d (883 &#8211; 909 MBOE/d) and cash capital expenditures between $3.8 billion and $4.2 billion. The company expects to drill between 446 and 471 gross (406 &#8211; 428 net) wells and complete between 557 and 592 gross (526 &#8211; 560 net) wells with an average lateral length of approximately 11,500 feet in 2025.
FANG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Diamondback Energy shares are up 1.62% after-hours at $157.75 Monday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit</a></li>
</ul>
Image: Shutterstock

Earnings

Commodities

FANG

Diamondback Energy Shares Edge Higher After Q4 Report

ACCD

Transcarent And Accolade Report Expiration Of HSR Waiting Period For Pending Merger Transaction

Reflecting legacy Coterra growth in 2025 and pro forma growth in 2026 and 2027, our new three-year outlook (2025 through 2027), includes annual average oil growth of 5% or greater, annual average BOE growth of 0 to 5%, which includes legacy organic Coterra growth in 2025 and pro forma combined growth in 2026 and 2027, and an average annual capital range of $2.1 to $2.4 billion. At the recent strip, this would imply an average reinvestment rate (non-GAAP) below 50% over the three-year period.

Guidance

CTRA

Coterra Energy Expects Three Year Outlook To Deliver Significant Free Cash Flow

Expect 1Q25 total equivalent production of 710 to 750 MBoepd, oil production of 134 to 144 MBopd, natural gas production of 2,850 to 3,000 MMcfpd, and capital expenditures of $525 to $625 million.
&nbsp;
&nbsp;
 &nbsp;

Dividends

Coterra Energy Expects 2025 Capital Expenditures Of $2.1B - $2.4B, Production Guidance Is Unchanged At The Midpoint From Framework Announced Last November

The new annualized dividend of $0.88 per share equates to a 3.1% yield, based on the Company's $28.14 closing share price as of February 21, 2025.

Coterra Energy Boosts Dividend 5% From $0.21 To $0.22 Per Share

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 19.26% on an annualized basis producing an average annual return of 34.41%. Currently, Spotify Technology has a market capitalization of $121.28 billion. 
Buying $1000 In SPOT: If an investor had bought $1000 of SPOT stock 5 years ago, it would be worth $4,472.60 today based on a price of $600.15 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740435309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPOT

Here's How Much $1000 Invested In Spotify Technology 5 Years Ago Would Be Worth Today

Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) reported fourth-quarter financial results Monday after the bell. Here&#8217;s a look at the key details<a href="https://www.benzinga.com/pressreleases/25/02/b43926808/cleveland-cliffs-reports-full-year-and-fourth-quarter-2024-results"> from the report</a>.
<ul>
<li>Q4 Revenue:&nbsp;$4.33 billion, versus&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $4.43 billion</li>
<li>Q4 EPS:&nbsp;Loss of 68 cents, versus estimates for a loss of 61 cents</li>
</ul>
Fourth-quarter steelmaking revenue&nbsp;included approximately&nbsp;$1.2 billion of sales to the infrastructure and manufacturing market, $1.2 billion of sales to direct automotive customers, $1.2 billion of sales to the distributors and converters market and&nbsp;$623 million of sales to steel producers.
Steel product sales totaled 3.8 million net tons&nbsp;in the fourth quarter, consisting of&nbsp;40%&nbsp;hot-rolled,&nbsp;26%&nbsp;coated,&nbsp;16%&nbsp;cold-rolled,&nbsp;5%&nbsp;plate,&nbsp;3%&nbsp;stainless and electrical and&nbsp;10%&nbsp;other, including slabs and rail.
&#8220;Our results in 2024 were a consequence of the worst steel demand environment since 2010 (ex-COVID). Cleveland-Cliffs is an American steel company, designed to supply high-end manufacturers producing things in the United States. That said, for the first time, the number of cars sold in the United States that were produced abroad and imported into the United States surpassed the number of cars sold that were produced domestically. With this decline in domestic automotive production, and too much imported steel from abroad that drove unsustainably low steel prices, Cliffs was deeply impacted,&#8221; said&nbsp;Lourenco Goncalves, chairman, president and CEO of Cleveland-Cliffs.
&#8220;This impact was particularly evident in the&nbsp;fourth quarter, which we expect to be the trough going forward. Our cash use in the&nbsp;fourth quarter, due largely to inventory build, has set us up nicely for the rebound we are seeing so far in 2025.&#8221;
Outlook: Cleveland-Cliffs expects full-year 2025 steel unit cost reductions of approximately $40 per net ton. The company anticipates full-year capital expenditures of approximately $700 million. 
Cleveland-Cliffs executives will further discuss the quarter on a conference call scheduled for 8:30 a.m. ET Tuesday morning. 
CLF Price Action: <a href="http://benzinga.com/quote/clf">Cleveland-Cliffs shares</a> were down 2.96% after hours, trading at $10.82 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Check This Out: • <a href="https://www.benzinga.com/general/health-care/25/02/43926641/hims-hers-health-stock-drops-after-q4-report-eps-in-line-revenues-beat">Hims &amp; Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat</a>
Photo: Shutterstock.

Cleveland-Cliffs Stock Slides On Q4 Earnings: The Details

TCOM

Trip.com Group Q4 Adj EPADS $0.60 Beats $0.52 Estimate, Sales $1.75B Beat $1.69B Estimate

Bitcoin miner Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/n43926811/riot-platforms-reports-full-year-2024-financial-results-current-operational-and-financial-highligh">details from the report. </a>
The Details: Riot Platforms reported fiscal 2024 revenue of $376.7 million, which beat the analyst consensus estimate of $372.34 million.
For fiscal 2024: 
<ul>
<li>Total revenue of $376.7 million, as compared to $280.7 million for 2023. The increase was primarily driven by a $132 million increase in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue.</li>
<li>Produced 4,828 Bitcoin as compared to 6,626 during the same 12-month period in 2023.</li>
<li>The average cost to mine Bitcoin, excluding depreciation, was $32,216 in 2024, as compared to $3,831 per Bitcoin in 2023. The increase was primarily driven by a 53% decrease in power credits received in FY 2024 relative to power credits received in FY 2023, the block subsidy &#8220;halving&#8221; event, which occurred in April 2024, and a 67% increase in the average global network hash rate as compared to the same period in 2023.</li>
<li>Bitcoin mining revenue of $321 million for the year, as compared to $189.0 million for the same 12-month period in 2023, primarily driven by higher average Bitcoin prices and an increase in operational hash rate, partially offset by an increase in network difficulty and the block subsidy &#8216;halving&#8217; event.</li>
<li>Engineering revenue of $38.5 million for the year, as compared to $64.3 million for the same 12-month period in 2023.</li>
<li>Held 17,722 unencumbered Bitcoin, equating to approximately $1.65 billion based on a market price for one Bitcoin on Dec.31, 2024, of $93,354. </li>
</ul>
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43920295/palantir-extends-losses-microsoft-slides-whats-driving-markets-monday">Palantir Extends Losses, Microsoft Slides: What&#8217;s Driving Markets Monday?&nbsp;</a>
&#8220;Riot had a remarkable year in 2024, generating record revenue of&nbsp;$376.7 million&nbsp;and net income of&nbsp;$109.4 million,&#8221; said Jason Les, CEO of Riot. 
&#8220;These results are particularly noteworthy in the context of the&nbsp;Bitcoin&nbsp;network&#8217;s &#8216;halving&#8217; in April of 2024, and an increase in global hash rate of 67% over the course of the year. Riot also generated record adjusted EBITDA of&nbsp;$463.2 million&nbsp;in 2024, demonstrating the value of our&nbsp;Bitcoin&nbsp;treasury policy of retaining&nbsp;Bitcoin&nbsp;production rather than selling,&#8221; Les added. 
RIOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Riot Platforms shares are up 3.50% after-hours at $10.34 Monday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

RIOT

Riot Platforms Shares Climb After FY 2024 Results: Details

Buybacks

Toronto-Dominion Bank Receives Regulatory Approval For Previously Announced Normal Course Issuer Bid To Buy For Cancellation Up To 100M Of Common Shares

BREA

Brera Holdings Signs Letter Of Intent To Further Invest In Mozambican Football Team Black Bulls

Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) is looking for FY2025 GAAP EPS of $1.50-$1.60&nbsp;

Apartment Inv & Mgmt Sees FY2025 GAAP EPS $1.50-$1.60

Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.43 by 13.95 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $1.40 billion which met the analyst consensus estimate. This is a 12.59 percent decrease over sales of $1.60 billion the same period last year.

Earnings Beats

Coterra Energy Q4 2024 Adj EPS $0.49 Beats $0.43 Estimate, Sales $1.395B Miss $1.404B Estimate

Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Travere Therapeutics and provided 12-month price targets. The average target is $35.8, accompanied by a high estimate of $45.00 and a low estimate of $22.00. This current average has increased by 36.64% from the previous average price target of $26.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1740434548_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Travere Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carly Kenselaar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Liisa Bayko</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travere Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Travere Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TVTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Travere Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Travere Therapeutics: A Closer Look</h2>
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
<h3>Travere Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Travere Therapeutics showcased positive performance, achieving a revenue growth rate of 18.9% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -80.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -421.09%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.97%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Travere Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 6.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TVTX

Analyst Expectations For Travere Therapeutics's Future

Ratings for Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $59.5, a high estimate of $69.00, and a low estimate of $49.00. This upward trend is apparent, with the current average reflecting a 2.25% increase from the previous average price target of $58.19.
<img src="https://www.benzinga.com/files/images/story/2025/1740434534_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Las Vegas Sands is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>George Choi</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$64.50</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Joseph Greff</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Las Vegas Sands. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Las Vegas Sands compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Las Vegas Sands's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Las Vegas Sands's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Las Vegas Sands analyst ratings.</a>
<h2>About Las Vegas Sands</h2>
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
<h3>Financial Insights: Las Vegas Sands</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Las Vegas Sands's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -0.65%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Las Vegas Sands's net margin is impressive, surpassing industry averages. With a net margin of 11.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Las Vegas Sands's ROE excels beyond industry benchmarks, reaching 10.27%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.54%, the company showcases effective utilization of assets.
Debt Management: Las Vegas Sands's debt-to-equity ratio is notably higher than the industry average. With a ratio of 4.77, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Las Vegas Sands Stock

Across the recent three months, 11 analysts have shared their insights on Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Globus Medical, revealing an average target of $97.36, a high estimate of $115.00, and a low estimate of $90.00. This current average has increased by 8.5% from the previous average price target of $89.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1740434522_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$83.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Globus Medical's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Globus Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GMED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Globus Medical analyst ratings.</a>
<h2>All You Need to Know About Globus Medical</h2>
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
<h3>Globus Medical: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Globus Medical's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 6.61%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Globus Medical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Globus Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.64%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Globus Medical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.51%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Connexa Sports Techs

ニュース

最新ニュース Connexa Sports Techs (NASDAQ:YYAI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル